

## The path to Catalyst Pathways® support starts with a completed Enrollment Form

Catalyst Pathways is a comprehensive program that assists patients and their families throughout their treatment journey. It can help your patients receive delivery of AGAMREE® (vamorolone) oral suspension 40 mg/mL, determine insurance coverage, understand out-of-pocket costs, and access a variety of educational resources.

Signup can be completed in three easy steps:

STEP 1

### Complete the Enrollment Form in its entirety.

- Sections 1 and 2 can be filled out by the patient/caregiver or the prescriber.
- Sections 3, 4, and 5 should be filled out by the prescriber.
  - Section 4 is the prescription (Rx) and should be filled out according to the label on the AGAMREE® package insert.
  - Section 5 includes Medical Criteria that should be filled out by the prescriber. This section validates the patient's diagnosis.
- Prescriber must sign and date where indicated on page 1.
- Patient/caregiver must sign and date where indicated on page 1.
- Please include a copy of the patient's insurance card (front and back).

Catalyst Pathways provides helpful educational materials and one-on-one dosing support to help ensure that patients achieve their optimal therapeutic dose. If there are delays in verifying your patients' insurance coverage, they may be eligible to receive up to 60 days of free medication under the Catalyst Bridge program.

STEP 2

The patient/caregiver must sign and date the Patient Authorization of the Enrollment Form (Section 6 on page 2) to be enrolled in Catalyst Pathways.

This step is necessary in order for Catalyst Pathways personnel to communicate with the patient's healthcare provider, insurance company, and financial assistance organizations (as necessary).

STEP 3

Fax the signed Enrollment Form to Catalyst Pathways at 1-888-981-9881.



# **ENROLLMENT FORM**

AGAMREE® (vamorolone) oral suspension 40 mg/mL

Fax #: 1-888-981-9881 Phone #: 1-833-4-CATALYST (1-833-422-8259) \*Please submit both pages

Please Submit both pages			
SECTION 1 - Patient Information (to be filled in by prescriber or patient/care	giver)		
Last Name: First Name:	DOB: Sex:		
Address: City:	State: ZIP:		
Phone (please check preferred): Home: ()	Work: () Cell: ()		
Caregiver Name: Relationship to I	Patient: Phone #: ()		
Emergency Contact:	Phone #: ()		
SECTION 2 - Insurance Information (to be filled in by prescriber or patient/cal	regiver). Please fax copies of the patient's insurance card (front and back).		
Patient Uninsured Primary Insurance Company Name:	Phone #: ()		
Policyholder Name: Policy #:			
Prescription Card Name:			
Policy #:			
Secondary Insurance Company Name:			
Policyholder Name:Policy #:	Group #		
SECTION 3 - Prescriber Information (to be filled in by prescriber only)			
Prescriber Name:	. NPI: DEA:		
Address:	Physician Tax ID #:		
City:	State: ZIP: State License #:		
Name of Contact Person:	. Phone #: () Preferred method of communication:		
Prescriber Email:			
SECTION A. Dr. (to be filled in by prescriber only)	SECTION 5 Madical Criteria (to be filled in by preseriber only)		
SECTION 4 - Rx (to be filled in by prescriber only)	SECTION 5 - Medical Criteria (to be filled in by prescriber only) ICD-10 Code G71.01		
AGAMREE® (vamorolone) oral suspension 40 mg/mL:  Dose:	Confirm patient has Duchenne muscular dystrophy (DMD):		
6 mg/kg/day: not to exceed the daily maximum dosage of 300 mg (7.5 mL)	Yes No		
Other (mg/kg/day)	Tested for DMD:		
Route of Administration:	Genetic test Creatine kinase Muscle biopsy		
By mouth G-tube Other:			
Days Supply: 30 60 90 Other: Refills:	Height: kg lb		
The recommended once-daily starting     Decrease dosage gradually when	Gene therapy: Yes No		
dosage is 6 mg/kg/day with a maximum dose of 300 mg (7.5 mL).  administered for more than one week AGAMREE Oral Suspension should	Exon-skipping therapy: Current Discontinued Never		
The recommended once-daily dosage     be taken once daily with or without foo	d. Corticosteroids (eg, prednisone): Current Discontinued Never		
of AGAMREE in patients with mild to moderate hepatic impairment is	EMFLAZA (deflazacort): Current Discontinued Never		
2 mg/kg/day with a maximum daily dose of 100 mg (2.5 mL).	Allergies:		
By signing below, I certify that (1) the above therapy is medically necessary and in the permission from the patient (or the patient's Legal Representative) and met any other Health Insurance Portability and Accountability Act of 1996 and/or state law needed its agents; (3) I have obtained the patient's authorization to release the above inform Services, LLC, as Catalyst's agent, and its employees to assist in obtaining coverage agent for the purpose of conveying this prescription to the appropriate dispensing pheroviding information regarding payer coverage and benefits and how to prepare pricinates, and providing me and my patient with educational and support services associated in the providing me and my patient with educational and support services associated in the patient's authorization to release the above information to release the above	er applicable legal or regulatory requirements such as those imposed under the to release the above information to Catalyst Pharmaceuticals, Inc. (Catalyst) and ation and such other information as may be required by AnovoRx Manufacturer er for this drug; and (4) I appoint AnovoRx Manufacturer Services, LLC, as my armacy, verifying the patient's insurance coverage for AGAMREE® (vamorolone), or authorization requests, coverage determination appeals, or other coverage incitated with AGAMREE® (vamorolone).		
I have read and agree to the Patient Authorization included on the next page.			
Patient/Legal Guardian Signature: sign	Date:		
Signatory's Relationship to Patient:			



### **ENROLLMENT FORM**

AGAMREE® (vamorolone) oral suspension 40 mg/mL

Fax #: 1-888-981-9881 Phone #: 1-833-4-CATALYST (1-833-422-8259) \*Please submit both pages

Discounting	to any full Discourse Delicourse to account to the same	SECTION 6 - Patient Authorization	
	to our full Privacy Policy at www.catalystpharma.cor		
By signing to to disclose rhealth insurance of further authinsurance of insurance of insurance of the significant of the signif	my personal health information, including, but not lance, as well as all information provided on this found ticals, Inc. and its representatives, agents, contract horize Catalyst to use and disclose my Personal Formpanies, and patient assistance programs solely overage, providing financial assistance for copay of	Date of Birth:  ders, health plans, and pharmacy providers and any other custodian of my healthcare records limited to, information relating to my medical condition, treatment, care management, and rm and any information about my prescriptions ("Personal Health Information"), to Catalyst ctors, and affiliates (collectively, "Catalyst") in order for Catalyst to provide product support services. Health Information to third parties, including, but not limited to, specialty pharmacies, health plans, or for such Catalyst Pathways product support services, including, but not limited to, investigating or out-of-pocket payments, eligibility for free medication supply, coordinating delivery of medication at my medical condition, treatment, care management, and health insurance.	
privacy laws for the purpo join Catalyst or eligibility	s and could be disclosed by Catalyst as well as oth oses outlined herein. I understand that signing this t Pathways and receive its services and benefits for	psed to third parties under this Authorization, may no longer be protected by state and federal the recipients of the information to others not identified in this Authorization as long as it is used a Authorization is voluntary but that if I decide not to sign this Authorization, I will not be eligible to be or which I may qualify. I also understand that my treatment, payment, enrollment in a health plan, rapy, is not conditioned on my signing this Authorization—only my eligibility for Catalyst Pathways. zation.	
notice of my 38134. Cata received the	y cancellation to the following address: Catalyst Falyst Pathways personnel will convey the cancellate Authorization. I also understand, however, that	Preceiving Catalyst Pathways services, and, if I choose to cancel, I must do so in writing by sending Pathways, c/o AnovoRx Manufacturer Services, LLC, 1710 N Shelby Oaks Dr., #3, Memphis, TN ation to all of my healthcare providers, health plans, and pharmacy providers that have previously any such cancellation will not apply to any information already used or disclosed based on this This Authorization expires five (5) years from the date signed below.	
pharmacy, a Program Ter	along with my prescription and any assistance with	; if confirmed as eligible, I understand that Copay Card information will be sent to my specialty my cost-sharing or copayment for AGAMREE® (vamorolone) will be made in accordance with the sy provide compensation to my pharmacy provider in exchange for data and/or Catalyst Pathways	
	(The following checkboxes describe	e additional <u>voluntary</u> programs in which you may choose to participate.)	
check	I acknowledge that by checking this box, I expressly consent to receive text messages from or on behalf of the Catalyst Pathways Patient Support activities at the mobile number(s) that I provide. Not checking this box will only allow Catalyst Pathways to communicate with me through calls, emails, and the mail.		
	numbers change in the future. I understand th	le telephone number(s) provided, and I agree to notify Catalyst Pathways promptly if any of my at my wireless service provider's message and data rates may apply. I understand that I can opt STOP to any text. I also understand that additional text messaging terms and conditions may be n confirmation text message.	
check		nal resources about AGAMREE® (vamorolone), as well as updates from Catalyst Pharmaceuticals. ommunications by calling 1-833-4-CATALYST (1-833-422-8259) or unsubscribing at the link provided	
	Email Address:		
Patient/Lega	al Guardian Signature: sign	Date:	
I, the patien disclose per	t or legal guardian(s), authorize the following indiversonal and medical information about me to Cataly	ridual(s) to act as my representative(s). These individual(s) have my full permission to obtain and rest and its agents and contractors.	
Patient/Lega	al Guardian Signature: sign	Date:	
Name of Pa	tient Representative:	Relationship to Patient:	

PLEASE FAX TO 1-888-981-9881

\_\_\_\_\_ Mobile #: (\_\_\_\_)\_\_\_

Telephone Inquiries: 1-833-4-CATALYST (1-833-422-8259)


Home Phone #: (\_\_\_\_)\_\_\_\_

# Instructions for Use AGAMREE® (ah gam' ree) (vamorolone) 40 mg/mL oral suspension

Read this Instructions for Use before you start using AGAMREE oral suspension and each time you get a new bottle. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

### Supplies provided in the AGAMREE carton:

- 1 bottle containing 100 mL of AGAMREE, with a child-resistant cap
- 1 bottle adapter
- Two 5 mL oral syringes
- 1 Prescribing information with Instructions for Use



#### Important information you need to know before taking AGAMREE:

- For oral use only (take by mouth).
- Always use the oral syringes provided with your AGAMREE oral suspension to make sure you measure the right amount.
- Ask your healthcare provider or pharmacist to show you how to measure your prescribed daily dose using the oral syringe.
- Call your pharmacist if your oral syringes are lost or damaged.
- Each oral syringe can be used for 45 days. Call your pharmacist if you need more oral syringes.
- Take AGAMREE exactly as your healthcare provider tells you to take it. **Do not** stop taking AGAMREE suddenly without first speaking with your healthcare provider.
- AGAMREE oral suspension should be taken 1-time daily with a meal.
- **Do not** mix the AGAMREE oral suspension with any type of liquids before taking or giving the prescribed daily dose.
- **Do not** use AGAMREE 3 months after opening the bottle. Write the date of first opening on your AGAMREE bottle when you first open it.

## **Storing AGAMREE**

- Store the unopened bottle upright at room temperature between 68°F to 77°F (20°C to 25°C) in the original carton. After opening the bottle, store the bottle upright in a refrigerator between 36°F to 46°F (2°C to 8°C).
- Do not freeze.
- Throw away (discard) any unused AGAMREE oral suspension remaining after 3 months of first opening the bottle.

### Keep AGAMREE oral suspension and all medicines out of the reach of children.

	Preparing the AGAMREE bottle				
Step 1	Place the child-resistant bottle cap on the bottle.  Make sure the child-resistant bottle cap is tightly secured and shake the bottle well for about 30 seconds.				
Step 2	Open the bottle by firmly pressing down on the child-resistant bottle cap and turning it to the left (counter-clockwise).  Do not throw away the child-resistant bottle cap.				
Step 3	Place the open bottle on a flat surface.  Firmly insert the bottle adapter into the bottle by pushing it tightly into the top of the bottle.  The top edge of the bottle adapter should be even with the bottle top.  Do not remove the bottle adapter after it is inserted into the bottle.  Write the date of first opening on your AGAMREE bottle when you first open it.				
	Preparing and withdrawing the AGAMREE dose				
Step 4	Check your dose in millilitres (mL) as prescribed by your healthcare provider. Each mark on the oral syringe is equal to 0.1 mL.  Do not take more than the prescribed daily dose.				

Before inserting the tip of the oral syringe into the bottle adapter, push the plunger completely down toward the tip of the oral syringe. Use 1 hand to hold the bottle upright. Insert the oral syringe tip firmly into the opening	
of the bottle adapter.	
Step 6 Hold the oral syringe in place and carefully turn the bottle upside down.  Pull the plunger down slowly until you reach the mL markings on the plunger for the prescribed dose.  Do not pull the plunger out of the oral dispenser.	
Step 7 If there are large bubbles in the oral syringe or if you draw up the wrong dose of AGAMREE, push the plunger all the way up so that AGAMREE flows back into the bottle. Pull the plunger down slowly until you reach the mL markings for your prescribed dose. Repeat Step 7 if any large air bubbles remain or if you draw up the wrong dose of AGAMREE.	
Step 8  Leave the tip of the oral syringe in the bottle and turn the entire bottle to an upright position. Slowly remove the oral syringe tip from the bottle by pulling the oral syringe straight up.  Do not hold the oral syringe by the plunger, because the plunger may come out.  Take or give AGAMREE right away after it is drawn up into	
the oral syringe.  Do not store the filled oral syringe.	

	Taking AGAMREE					
Step 9	The child or adult should sit upright to take a dose of AGAMREE.  Place the oral syringe tip in the mouth towards the cheek and slowly push the plunger down until the oral syringe is empty.  Do not forcefully push on the plunger. Do not give AGAMREE too fast into the back of the mouth or throat. This may cause choking.					
Step 10	If your prescribed dose is greater than 5 mL, repeat <b>Steps 4 to 9</b> .					
		iving AGAMREE				
Step 11	Put the child-resistant bottle cap back on the bottle and turn the cap to the right (clockwise) to close the bottle. Keep the bottle tightly closed after each use.					
	Cleaning the	oral syringes				
Step 12	Remove the plunger from the barrel of the oral syringe.  Rinse the barrel and plunger with running warm water only and let them air dry on a paper towel.  When the oral syringe and plunger are dry, put the plunger back in the oral syringe for the next dose. Store the oral syringe in a clean, dry place.					

For further information call 1-833-422-8259 or go to www.YourCatalystPathways.com.

Manufactured for: Catalyst Pharmaceuticals, Inc., Coral Gables, FL 33134

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Revised: 03/2024